Liquid Nitrogen Cryoballoon Ablation System for Paroxysmal Atrial Fibrillation: A Multicenter, Prospective,...

Area of Science:

• Cardiology
• Medical Devices
• Electrophysiology

Background:

• Cryoballoon ablation (CBA) is a recognized treatment for atrial fibrillation (AF).
• Drug-resistant paroxysmal atrial fibrillation (PAF) requires effective therapeutic options.

Purpose of the Study:

• To evaluate the performance, safety, and efficacy of a novel liquid nitrogen-driven CBA system.
• To assess the treatment success and adverse event profile in patients with drug-resistant PAF.

Main Methods:

• A prospective, multicenter, single-arm clinical trial involving 176 patients with PAF.
• Patients underwent pulmonary vein isolation using the liquid nitrogen-driven CBA system.
• Follow-up assessments were conducted at 3, 6, and 12 months post-procedure.

Main Results:

• The 12-month treatment success rate was 82.56%, with an immediate pulmonary vein isolation success rate of 97.67%.
• Device-related adverse events occurred in 2.27% of patients, and procedure-related adverse events in 25.00%.
• One case of permanent phrenic nerve palsy was reported, with overall severe adverse events at 17.05%.

Conclusions:

• The liquid nitrogen-driven cryoballoon ablation system is a safe and effective treatment for paroxysmal atrial fibrillation.
• This premarketing study supports the use of this novel CBA system for drug-resistant PAF.